An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder

Status:	Completed
Conditions:	Depression, Depression, Major Depression Disorder (MDD)
Therapuetic Areas:	Psychiatry / Psychology, Pulmonary / Respiratory Diseases
Healthy:	No
Age Range:	18 - 64
Updated:	11/23/2017
Start Date:	March 2003
End Date:	April 2007

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.

A Placebo Controlled Study Evaluating Efficacy, Safety and Tolerability of Medication in
Patients with Major Depressive Disorder (MDD)

Inclusion Criteria:

- Diagnosis of Major Depressive Disorder (MDD)

- Duration of current depressive episode 12 weeks - 24 months

- Patients can read and write at a level sufficient to provide a signed consent

- If female, patients must be practicing an acceptable method of birth control

Exclusion Criteria:

- Patients have other psychiatric disorders that would affect patient's response to
treatment

- Patients have not responded to two or more adequate courses of antidepressant therapy

- Patients cannot be currently abusing illicit drugs or alcohol

- Patients are not currently receiving psychotherapy

- Patients have received electroconvulsive therapy within 6 months prior to screening

- Patients are pregnant or lactating

We found this trial at

sites

An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder

Use our guide to learn which trials are right for you!

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible-Dose Study Evaluating Efficacy, Safety, and Tolerability of Once-Daily Oral GW353162 (20-40-60mg) Versus Placebo in Subjects With Major Depressive Disorder Over an Eight-Week Treatment Period.

Select your condition

Common Conditions

All Conditions